[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"app-context":3,"blog-ocular-therapeutix-stock-jumps-22-8-after-conference-update-ahead-of-earnings-FR":150},{"languages":4,"categories":41,"products":125,"competitors":149},[5,9,13,17,21,25,29,33,37],{"name":6,"code":7,"id":8},"English","EN","TGFuZ3VhZ2U6ZW4=",{"name":10,"code":11,"id":12},"Español","ES","TGFuZ3VhZ2U6ZXM=",{"name":14,"code":15,"id":16},"Português","PT","TGFuZ3VhZ2U6cHQ=",{"name":18,"code":19,"id":20},"日本語","JA","TGFuZ3VhZ2U6amE=",{"name":22,"code":23,"id":24},"한국어","KO","TGFuZ3VhZ2U6a28=",{"name":26,"code":27,"id":28},"Deutsch","DE","TGFuZ3VhZ2U6ZGU=",{"name":30,"code":31,"id":32},"Italiano","IT","TGFuZ3VhZ2U6aXQ=",{"name":34,"code":35,"id":36},"Français","FR","TGFuZ3VhZ2U6ZnI=",{"name":38,"code":39,"id":40},"中文 (中国)","ZH","TGFuZ3VhZ2U6emg=",[42,73,104],{"icon":43,"slug":44,"title":45,"description":46,"featuredLinks":47},"mingcute:stock-line","stock-market-basics","Stock Market Basics","\u003Cp>Beginners' guides and practical tips for understanding stock market investing.\u003C\u002Fp>\n",[48,53,58,63,68],{"url":49,"title":50,"description":51,"ogImage":52},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-makes-stocks-go-up-and-down","What Makes Stocks Go Up and Down | TIKR.com","Understanding what makes stock prices go up and down can help investors better navigate investing. Click to learn more!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-makes-stocks-go-up-and-down-banner\u002FWhat-makes-stocks-go-up-and-down-banner.jpg?_i=AA",{"url":54,"title":55,"description":56,"ogImage":57},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fdividend-yield-meaning-formula-example","Dividend Yield: Meaning, Formula, Example | Tikr.com Blog | TIKR.com","The dividend yield is a key metric for investors looking to gauge the income potential of their investments. It measures how much a company pays out in","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FDividend-yield\u002FDividend-yield.png?_i=AA",{"url":59,"title":60,"description":61,"ogImage":62},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fmarket-capitalization-definition-formula-and-why-it-matters","Market Capitalization: Definition, Formula, and Why It Matters | TIKR.com","Long-term investors often look at various valuation metrics when deciding whether to invest in a particular company. One helpful metric to evaluate is","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FMarket-Capitalization-Definition-Formula-and-Why-It-Matters\u002FMarket-Capitalization-Definition-Formula-and-Why-It-Matters.png?_i=AA",{"url":64,"title":65,"description":66,"ogImage":67},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fearnings-per-share-definition-formula-and-why-eps-matters","Earnings Per Share: Definition, Formula, and Why EPS Matters | TIKR.com","Earnings Per Share (EPS) represents the portion of a company's net earnings allocated to each share. Click to learn more!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEPS-Defiinition-formula-and-why-EPS-matters-1\u002FEPS-Defiinition-formula-and-why-EPS-matters-1.png?_i=AA",{"url":69,"title":70,"description":71,"ogImage":72},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-stock-price-target","What Is a Stock Price Target? | TIKR.com","A price target is a stock's estimated future price. It can help investors quickly find undervalued stocks. Learn more now!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-Stock-Price-Target-2\u002FWhat-is-a-Stock-Price-Target-2.png?_i=AA",{"icon":74,"slug":75,"title":76,"description":77,"featuredLinks":78},"material-symbols:analytics-outline","fundamental-analysis","Fundamental Analysis","\u003Cp>In-depth resources and financial metrics to help you evaluate companies like a pro.\u003C\u002Fp>\n",[79,84,89,94,99],{"url":80,"title":81,"description":82,"ogImage":83},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fshare-repurchase-why-do-companies-buy-back-their-stock","Share Repurchase: Why Do Companies Buy Back Their Stock? | TIKR.com","Share repurchases, or share buybacks, have gained popularity in the last two decades. According to a report from Goldman Sachs, stock buybacks initiated","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FTIKR-BLOG-COVER-PHOTOS-3_544a7f4e\u002FTIKR-BLOG-COVER-PHOTOS-3_544a7f4e.png?_i=AA",{"url":85,"title":86,"description":87,"ogImage":88},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-return-on-invested-capital","What Is a Good Return on Invested Capital? | TIKR.com","Learning about Return on Invested Capital (ROIC) can help investors spot highly profitable stocks that can drive long-term returns. Learn more now!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-return-on-Invested-capital\u002FWhat-is-a-good-return-on-Invested-capital.png?_i=AA",{"url":90,"title":91,"description":92,"ogImage":93},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-return-on-equity-ratio","What is a Good Return on Equity Ratio | Tikr.com Blog | TIKR.com","Return on Equity (ROE) is a financial ratio that reflects a company's profitability in relation to the equity invested by shareholders. It basically","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-return-on-equity-ratio-1\u002FWhat-is-a-good-return-on-equity-ratio-1.jpg?_i=AA",{"url":95,"title":96,"description":97,"ogImage":98},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-p-e-ratio","What Is a Good P\u002FE Ratio? | TIKR.com","Financial analysts and investors look at various metrics before deciding whether a stock is a buy. One of the metrics is the price-to-earnings ratio (P\u002FE","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-PE-ratio-1\u002FWhat-is-a-good-PE-ratio-1.jpg?_i=AA",{"url":100,"title":101,"description":102,"ogImage":103},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Ftop-6-metrics-for-investing-in-reits","Top 6 Metrics for Investing in REITs | TIKR.com","Real estate has been one of the greatest asset classes for wealth creation in history, and investing in Real Estate Investment Trusts (REITs) can allow","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FGroup-10\u002FGroup-10.png?_i=AA",{"icon":105,"slug":106,"title":107,"description":108,"featuredLinks":109},"hugeicons:investigation","investing-lingo","Investing Lingo","\u003Cp>A comprehensive glossary of investing terms and jargon so you can speak the language of the markets confidently.\u003C\u002Fp>\n",[110,115,120],{"url":111,"title":112,"description":113,"ogImage":114},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fenterprise-value-definition-and-calculation","Enterprise Value: Definition and Calculation | Tikr.com Blog | TIKR.com","Enterprise value (EV) is a financial metric that offers a comprehensive snapshot of a company's total value. Unlike market capitalization which solely","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEnterprise-Value-Definition-and-Calculation_37576e40\u002FEnterprise-Value-Definition-and-Calculation_37576e40.png?_i=AA",{"url":116,"title":117,"description":118,"ogImage":119},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Febitda-definition-formula-how-to-use-it","EBITDA: Definition, Formula, How to Use It | TIKR.com","EBITDA stands for earnings before interest, taxes, depreciation and amortization. It's a financial metric commonly used to evaluate a company's financial","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEBITDA-Definition-Formula-How-to-Use-It\u002FEBITDA-Definition-Formula-How-to-Use-It.png?_i=AA",{"url":121,"title":122,"description":123,"ogImage":124},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-the-free-cash-flow-formula-and-why-does-it-matter","What is the Free Cash Flow Formula and Why Does It Matter | TIKR.com","Free cash flow, or FCF, is the cash a company generates after it accounts for outflows required to maintain business operations and support capital","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-the-free-cash-flow-formula\u002FWhat-is-the-free-cash-flow-formula.png?_i=AA",[126,130,134,137,141,145],{"slug":127,"modified":128,"title":129},"valuation-model-builder","2025-07-03T00:18:53","Value Stocks Quickly and Accurately",{"slug":131,"modified":132,"title":133},"stock-portfolio-tracking","2024-12-02T22:21:28","Monitor Your Portfolio",{"slug":75,"modified":135,"title":136},"2025-01-21T22:10:52","Instantly Analyze Companies with In-Depth Metrics",{"slug":138,"modified":139,"title":140},"stock-screener","2024-12-02T22:13:31","Find the Best Stocks to Buy",{"slug":142,"modified":143,"title":144},"investor-stock-portfolio","2025-01-21T22:02:56","Follow Investment Moves of Top Investors",{"slug":146,"modified":147,"title":148},"analyze-stocks","2025-07-23T16:04:24","Analyze Stocks",[],{"post":151,"seo":187,"relatedPosts":193,"suggestedPosts":273},{"id":152,"title":153,"date":154,"modified":155,"excerpt":156,"content":157,"wordCount":158,"lang":159,"uri":160,"slug":161,"cloudinaryAssetId":162,"featuredImageOriginalUrl":163,"featuredImageMetadata":164,"author":167,"editor":173,"categories":178,"relatedPosts":184,"seo":185},95533,"L'action d'Ocular Therapeutix bondit de 22,8 % après la conférence qui a précédé la publication des résultats","2026-03-03T13:05:00","2026-03-03T13:02:20","\u003Cp>Voici pourquoi l'action d'Ocular Therapeutix (OCUL) a bondi de 23% après les nouvelles mises à jour des investisseurs avant la publication des résultats.\u003C\u002Fp>\n","\n\u003Ch2 class=\"wp-block-heading\" id=\"h-k-ey-stats-for-ocul-stock\">\u003Cstrong>Principales statistiques\u003C\u002Fstrong> pour l'\u003Cstrong>action\u003Cstrong>OCUL\u003C\u002Fstrong>\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cul class=\"wp-block-list\">\n\u003Cli>\u003Cstrong>Variation du cours de l'action \u003Cstrong>OCUL\u003C\u002Fstrong>:\u003C\u002Fstrong> +22.8%\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>\u003Cstrong>OCUL\u003C\u002Fstrong>\u003C\u002Fstrong> \u003Cstrong>Cours de l'action au \u003Cstrong>02 mars\u003C\u002Fstrong>:\u003C\u002Fstrong> 11\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Plus haut sur 52 semaines :\u003C\u002Fstrong> 16\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>\u003Cstrong>OCUL\u003C\u002Fstrong>\u003C\u002Fstrong> \u003Cstrong>Objectif de cours : \u003C\u002Fstrong> 25\u003C\u002Fli>\n\u003C\u002Ful>\n\n\n\n\u003Cp>\u003Cem>\u003Cstrong>\u003Cem>\u003Cstrong>\u003Cstrong>\u003Cem>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\" target=\"_blank\" rel=\"noreferrer noopener\">Maintenant en ligne : Découvrez le potentiel de hausse de vos actions préférées en utilisant le nouveau modèle d'évaluation de TIKR (c'est gratuit).\u003C\u002Fa>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fem>\u003Cstrong>\u003Cem>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">>>>\u003C\u002Fa>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-what-happened\">Que s'est-il passé ?\u003C\u002Fh2>\n\n\n\n\u003Cp>Ocular Therapeutix, Inc. (\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">OCUL\u003C\u002Fa>\u003C\u002Fstrong>) a fait un bond de 22,8 % le 2 mars et a clôturé à 10,98 $. Le mouvement a suivi la présentation de la société à la TD Cowen 46th Annual Health Care Conference et un appel spécial le même jour. Les investisseurs ont réagi lorsque la direction a parlé de l'avancement du pipeline et des étapes à venir. Le volume des transactions a également dépassé sa moyenne de 5,9 millions sur trois mois.\u003C\u002Fp>\n\n\n\n\u003Cp>La société a récemment fait une présentation lors de la 49e réunion annuelle de la Macula Society à la fin du mois de février. Ces apparitions ont eu lieu quelques jours avant qu'Ocular Therapeutix ne présente ses résultats pour l'année fiscale 2025, le 6 mars. Étant donné que les actions biotechnologiques sont tributaires des événements, les commentaires des conférences sont souvent à l'origine des mouvements à court terme. Les investisseurs semblent se positionner avant les résultats.\u003C\u002Fp>\n\n\n\n\u003Cp>Ocular Therapeutix développe des thérapies pour les maladies de la rétine et d'autres affections oculaires en utilisant sa plateforme d'administration basée sur l'hydrogel. Elle commercialise DEXTENZA et fait progresser AXPAXLI dans les essais de phase 3. La société poursuit également le développement d'OTX-TIC pour le glaucome. Les mises à jour du pipeline restent donc le principal moteur de l'évaluation.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Cstrong>\u003Cem>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">Voir les prévisions de croissance et les objectifs de prix des analystes pour l'action OCUL (C'est gratuit !) >>>\u003C\u002Fa>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-what-the-market-is-telling-us-about-ocul-stock\">Ce que le marché nous dit à propos du titre OCUL\u003C\u002Fh2>\n\n\n\n\u003Cp>La hausse de 22,8% suggère que les investisseurs sont encouragés par les récentes mises à jour et les catalyseurs à court terme. La société a actuellement une capitalisation boursière de 2,39 milliards de dollars et une valeur d'entreprise de 1,73 milliard de dollars. Les actions en circulation totalisent 217,7 millions, et le flottant s'élève à 87,6 %. L'action reste en dessous de son plus haut de 52 semaines, à 16 dollars.\u003C\u002Fp>\n\n\n\n\u003Cp>Ocular Therapeutix maintient également une position de trésorerie nette, avec une dette nette LTM négative de 660 millions de dollars. La solidité de son bilan lui confère une certaine flexibilité dans le financement de ses essais cliniques. \u003C\u002Fp>\n\n\n\n\u003Cfigure class=\"wp-block-image size-large\">\u003Cimg width=\"1024\" height=\"683\" data-public-id=\"images\u002FTIKR.com_OCUL-Ocular-Therapeutix-Inc.-Net-Debt_95542adefd\u002FTIKR.com_OCUL-Ocular-Therapeutix-Inc.-Net-Debt_95542adefd.webp\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1024,h_683,c_scale\u002Ff_webp,q_auto\u002Fv1772542625\u002Fimages\u002FTIKR.com_OCUL-Ocular-Therapeutix-Inc.-Net-Debt_95542adefd\u002FTIKR.com_OCUL-Ocular-Therapeutix-Inc.-Net-Debt_95542adefd.webp?_i=AA\" alt=\"\" class=\"wp-post-95533 wp-image-95542\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1772542625\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1024,h_683,c_scale\u002Ff_webp,q_auto\u002Fv1772542625\u002Fimages\u002FTIKR.com_OCUL-Ocular-Therapeutix-Inc.-Net-Debt_95542adefd\u002FTIKR.com_OCUL-Ocular-Therapeutix-Inc.-Net-Debt_95542adefd.webp?_i=AA 1024w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_300,h_200,c_scale\u002Ff_webp,q_auto\u002Fv1772542625\u002Fimages\u002FTIKR.com_OCUL-Ocular-Therapeutix-Inc.-Net-Debt_95542adefd\u002FTIKR.com_OCUL-Ocular-Therapeutix-Inc.-Net-Debt_95542adefd.webp?_i=AA 300w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_768,h_512,c_scale\u002Ff_webp,q_auto\u002Fv1772542625\u002Fimages\u002FTIKR.com_OCUL-Ocular-Therapeutix-Inc.-Net-Debt_95542adefd\u002FTIKR.com_OCUL-Ocular-Therapeutix-Inc.-Net-Debt_95542adefd.webp?_i=AA 768w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1536,h_1024,c_scale\u002Ff_webp,q_auto\u002Fv1772542625\u002Fimages\u002FTIKR.com_OCUL-Ocular-Therapeutix-Inc.-Net-Debt_95542adefd\u002FTIKR.com_OCUL-Ocular-Therapeutix-Inc.-Net-Debt_95542adefd.webp?_i=AA 1536w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_2048,h_1365,c_scale\u002Ff_webp,q_auto\u002Fv1772542625\u002Fimages\u002FTIKR.com_OCUL-Ocular-Therapeutix-Inc.-Net-Debt_95542adefd\u002FTIKR.com_OCUL-Ocular-Therapeutix-Inc.-Net-Debt_95542adefd.webp?_i=AA 2048w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772542625\u002Fimages\u002FTIKR.com_OCUL-Ocular-Therapeutix-Inc.-Net-Debt_95542adefd\u002FTIKR.com_OCUL-Ocular-Therapeutix-Inc.-Net-Debt_95542adefd.webp?_i=AA 600w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1200,h_800,c_scale\u002Ff_webp,q_auto\u002Fv1772542625\u002Fimages\u002FTIKR.com_OCUL-Ocular-Therapeutix-Inc.-Net-Debt_95542adefd\u002FTIKR.com_OCUL-Ocular-Therapeutix-Inc.-Net-Debt_95542adefd.webp?_i=AA 1200w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1400,h_933,c_scale\u002Ff_webp,q_auto\u002Fv1772542625\u002Fimages\u002FTIKR.com_OCUL-Ocular-Therapeutix-Inc.-Net-Debt_95542adefd\u002FTIKR.com_OCUL-Ocular-Therapeutix-Inc.-Net-Debt_95542adefd.webp?_i=AA 1400w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">Dette nette d'OCUL\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">(TIKR\u003C\u002Fa>)\u003C\u002Ffigcaption>\u003C\u002Ffigure>\n\n\n\n\u003Cp>Cependant, comme la plupart des biotechs en phase clinique, la société n'est pas encore constamment rentable. Les marges restent sous la pression des dépenses de recherche et de développement.\u003C\u002Fp>\n\n\n\n\u003Cp>Le bêta de l'action sur cinq ans, qui est de 0,9, indique une volatilité largement en ligne avec le marché, mais les catalyseurs biotechnologiques peuvent créer des mouvements brusques. Les bénéfices étant attendus pour le 6 mars, les investisseurs attendront des mises à jour sur les calendriers des essais et les liquidités disponibles. De nombreuses conférences sur les soins de santé sont également prévues tout au long du mois de mars. Le sentiment pourrait donc rester élevé à court terme.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Cstrong>\u003Cem>\u003Cstrong>\u003Cem>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cstrong>\u003Cem>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fa>\u003Cstrong>\u003Cem>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\" target=\"_blank\" rel=\"noreferrer noopener\">Estimez instantanément la juste valeur d'une entreprise (gratuit avec TIKR) >>>\u003C\u002Fa>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-should-you-invest-in-ocular-therapeutix-inc\">Devriez-vous investir dans Ocular Therapeutix, Inc.\u003C\u002Fh2>\n\n\n\n\u003Cp>La seule façon de le savoir est de regarder les chiffres vous-même. TIKR vous donne un accès gratuit aux mêmes \u003Cstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cmark style=\"background-color:rgba(0, 0, 0, 0);color:#666666\" class=\"has-inline-color\">données financières de qualité institutionnelle\u003C\u002Fmark>\u003C\u002Fa>\u003C\u002Fstrong> que les analystes professionnels utilisent pour répondre à cette question.\u003C\u002Fp>\n\n\n\n\u003Cp>En consultant OCUL, vous verrez des années de données financières historiques, les prévisions des analystes de Wall Street en matière de revenus et de bénéfices pour les trimestres à venir, l'évolution des multiples d'évaluation au fil du temps et la tendance à la hausse ou à la baisse des objectifs de prix.\u003C\u002Fp>\n\n\n\n\u003Cp>Vous pouvez \u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cmark style=\"background-color:rgba(0, 0, 0, 0);color:#666666\" class=\"has-inline-color\">\u003Cstrong>créer une liste de surveillance gratuite pour suivre OCUL\u003C\u002Fstrong>\u003C\u002Fmark>\u003C\u002Fa> ainsi que toutes les autres actions qui vous intéressent. Aucune carte de crédit n'est requise. Juste les données dont vous avez besoin pour décider par vous-même.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cstrong>\u003Cem>\u003Cstrong>Analyser l'action Ocular Therapeutix\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fstrong> \u003Cstrong>\u003Cstrong>\u003Cem>\u003Cstrong>\u003Cem>\u003Cstrong>sur TIKR \u003Cstrong>Free→\u003C\u002Fstrong> \u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-looking-for-new-opportunities\">À la recherche de nouvelles opportunités ?\u003C\u002Fh2>\n\n\n\n\u003Cul class=\"wp-block-list\">\n\u003Cli>Voyez quelles actions\u003Cstrong> \u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">les investisseurs milliardaires achètent\u003C\u002Fa> \u003C\u002Fstrong>afin que vous puissiez suivre l'argent intelligent.\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">Analysez les actions en seulement 5 minutes\u003C\u002Fa>\u003C\u002Fstrong> grâce à la plateforme tout-en-un et facile à utiliser de TIKR.\u003C\u002Fli>\n\n\n\n\u003Cli>Plus vous renversez de pierres... plus vous découvrirez d'opportunités. \u003Cstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">Recherchez plus de 100 000 actions mondiales, les titres des principaux investisseurs mondiaux, et plus encore avec TIKR.\u003C\u002Fa>\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\n\n\u003Ch2 class=\"wp-block-heading\">\u003Cstrong>Avis de non-responsabilité :\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cp>\u003Cem>Veuillez noter que les articles de TIKR ne sont pas destinés à servir de conseils financiers ou d'investissement de la part de TIKR ou de notre équipe de contenu, et qu'ils ne constituent pas non plus des recommandations d'achat ou de vente d'actions. Nous créons notre contenu en nous basant sur les données d'investissement de TIKR Terminal et sur les estimations des analystes. Notre analyse peut ne pas inclure des nouvelles récentes de l'entreprise ou des mises à jour importantes. TIKR n'a aucune position dans les actions mentionnées. Nous vous remercions de votre lecture et vous souhaitons de bons investissements !\u003C\u002Fem>\u003C\u002Fp>\n",637,"fr","\u002Fblog\u002Focular-therapeutix-stock-jumps-22-8-after-conference-update-ahead-of-earnings","ocular-therapeutix-stock-jumps-22-8-after-conference-update-ahead-of-earnings","images\u002FOCUL-stock\u002FOCUL-stock","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772542823\u002Fimages\u002FOCUL-stock\u002FOCUL-stock.png?_i=AA",{"altText":165,"imageCredit":166},"Ocular Therapeutix Stock Jumps 22.8% After Conference Update Ahead of Earnings","KTM_2016 from Getty Images via Canva",{"name":168,"slug":169,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":172},"Rexielyn Diaz","rexietikr","author","",[],{"name":174,"slug":175,"role":176,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":177},"Thomas Richmond","thomastikr","editor",[],[179],{"name":180,"slug":181,"uri":182,"description":171,"postsCount":183},"Examens des Actions","reviews","\u002Fblog\u002Fcategory\u002Freviews",0,[],{"title":165,"metaDesc":186,"opengraphDescription":186,"twitterTitle":165,"twitterDescription":186},"Here’s why Ocular Therapeutix (OCUL) stock surged 23% after fresh investor updates ahead of earnings.",{"title":165,"description":186,"twitterTitle":165,"twitterDescription":186,"author":168,"articlePublisher":188,"articlePublishedTime":154,"articleModifiedTime":155,"twitterLabel1":189,"twitterData1":190,"ogTitle":165,"ogDescription":186,"ogUrl":160,"ogImage":163,"ogImageWidth":191,"ogImageHeight":192,"ogImageSecureUrl":163,"ogImageAlt":165,"twitterImage":163},"TIKR.com","Temps de lecture estimé","5 minutes",1200,630,[194,211,228,243,258],{"id":183,"title":195,"date":196,"excerpt":197,"wordCount":198,"uri":199,"slug":200,"cloudinaryAssetId":201,"featuredImageOriginalUrl":202,"featuredImageMetadata":203,"author":204,"categories":208,"relatedPosts":210},"Ventas a réalisé 800 millions de dollars d'acquisitions le mois dernier : Ce que les investisseurs doivent savoir","2026-03-03 13:00:00","entas prévoit une cinquième année consécutive de croissance à deux chiffres du revenu net d'exploitation, avec un modèle d'évaluation indiquant un prix cible de 136 dollars et un rendement total de 57 % que le prix actuel de 86,66 dollars n'a pas encore reconnu.",763,"\u002Fblog\u002Fventas-closed-800-million-in-acquisitions-last-month-heres-what-investors-need-to-know","ventas-closed-800-million-in-acquisitions-last-month-heres-what-investors-need-to-know","images\u002FFEATURED-IMAGE-MAKER-386\u002FFEATURED-IMAGE-MAKER-386","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_360,c_scale\u002Ff_webp,q_auto\u002Fv1772531106\u002Fimages\u002FFEATURED-IMAGE-MAKER-386\u002FFEATURED-IMAGE-MAKER-386.png?_i=AA",{"altText":195},{"name":205,"slug":206,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":207},"Gian Estrada","giantikr",[],[209],{"name":180,"slug":181,"uri":182,"description":171,"postsCount":183},[],{"id":183,"title":212,"date":213,"excerpt":214,"wordCount":215,"uri":216,"slug":217,"cloudinaryAssetId":218,"featuredImageOriginalUrl":219,"featuredImageMetadata":220,"author":221,"categories":225,"relatedPosts":227},"Costco est en hausse de 16 % depuis le début de l'année. Voici où les actions pourraient aller en 2026","2026-03-03 12:35:00","Costco est en hausse d'environ 16 % depuis le début de l'année, après avoir annoncé une croissance des ventes de 9,3 % en janvier et une augmentation de 34,4 % de la masse salariale numérique. Voici pourquoi l'augmentation régulière du trafic, la forte rentabilité des adhésions et l'expansion disciplinée pourraient continuer à soutenir les actions jusqu'en 2026.",791,"\u002Fblog\u002Fcostco-is-up-16-year-to-date-heres-where-shares-could-go-in-2026","costco-is-up-16-year-to-date-heres-where-shares-could-go-in-2026","images\u002F@Erik-Mclean-from-Pexels-via-Canva-1\u002F@Erik-Mclean-from-Pexels-via-Canva-1","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772525636\u002Fimages\u002F@Erik-Mclean-from-Pexels-via-Canva-1\u002F@Erik-Mclean-from-Pexels-via-Canva-1.png?_i=AA",{"altText":212},{"name":222,"slug":223,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":224},"Nikko Henson","nikkotikr",[],[226],{"name":180,"slug":181,"uri":182,"description":171,"postsCount":183},[],{"id":183,"title":229,"date":230,"excerpt":231,"wordCount":232,"uri":233,"slug":234,"cloudinaryAssetId":235,"featuredImageOriginalUrl":236,"featuredImageMetadata":237,"author":238,"categories":240,"relatedPosts":242},"Lam Research a fait un bond de 138% au cours des 6 derniers mois. Voici à combien pourrait s'élever l'action en 2026","2026-03-03 12:05:00","Lam Research a progressé de 138% au cours des six derniers mois, et notre analyse suggère que le titre pourrait encore offrir une hausse supplémentaire jusqu'en 2026. Voici pourquoi l'accélération des dépenses en mémoires basées sur l'IA et l'augmentation du levier d'exploitation continuent de soutenir la configuration.",795,"\u002Fblog\u002Flam-research-surged-138-in-the-last-6-months-heres-how-much-the-stock-could-rise-in-2026","lam-research-surged-138-in-the-last-6-months-heres-how-much-the-stock-could-rise-in-2026","images\u002F@Wachiwit-from-Getty-Images-Pro-via-Canva\u002F@Wachiwit-from-Getty-Images-Pro-via-Canva","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772524559\u002Fimages\u002F@Wachiwit-from-Getty-Images-Pro-via-Canva\u002F@Wachiwit-from-Getty-Images-Pro-via-Canva.png?_i=AA",{"altText":229},{"name":222,"slug":223,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":239},[],[241],{"name":180,"slug":181,"uri":182,"description":171,"postsCount":183},[],{"id":183,"title":244,"date":245,"excerpt":246,"wordCount":247,"uri":248,"slug":249,"cloudinaryAssetId":250,"featuredImageOriginalUrl":251,"featuredImageMetadata":252,"author":253,"categories":255,"relatedPosts":257},"AbbVie atteint 31 milliards de dollars de ventes de Skyrizi et de Rinvoq","2026-03-03 12:00:00","Skyrizi vient de remporter son essai de phase 3 sur la maladie de Crohn par voie sous-cutanée, mais ce qui est plus important, c'est ce qui va suivre : l'approbation du tavapadon, les nouvelles indications de Rinvoq et une franchise de plus de 5 milliards de dollars sur la migraine que la Bourse n'a pas encore modélisée.",909,"\u002Fblog\u002Fabbvie-hits-31-billion-in-skyrizi-and-rinvoq-sales","abbvie-hits-31-billion-in-skyrizi-and-rinvoq-sales","images\u002FFEATURED-IMAGE-MAKER-385\u002FFEATURED-IMAGE-MAKER-385","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_360,c_scale\u002Ff_webp,q_auto\u002Fv1772530062\u002Fimages\u002FFEATURED-IMAGE-MAKER-385\u002FFEATURED-IMAGE-MAKER-385.png?_i=AA",{"altText":244},{"name":205,"slug":206,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":254},[],[256],{"name":180,"slug":181,"uri":182,"description":171,"postsCount":183},[],{"id":183,"title":259,"date":260,"excerpt":261,"wordCount":262,"uri":263,"slug":264,"cloudinaryAssetId":265,"featuredImageOriginalUrl":266,"featuredImageMetadata":267,"author":268,"categories":270,"relatedPosts":272},"L'action Cardinal Health en 2026 : pourquoi les analystes ont fixé un objectif moyen de 248 dollars","2026-03-03 11:29:00","Cardinal Health vient d'afficher une croissance de 36 % de son bénéfice par action et a relevé ses prévisions pour l'ensemble de l'année à 10,15-10,35 dollars, soit une projection de croissance de 23 % à 26 % qui remet en cause le plafond de bénéfices que les investisseurs pensaient que cette société avait à leur disposition.\n",832,"\u002Fblog\u002Fcardinal-health-stock-is-up-90-from-its-52-week-low-why-analysts-see-more-upside-in-2026","cardinal-health-stock-is-up-90-from-its-52-week-low-why-analysts-see-more-upside-in-2026","images\u002FFEATURED-IMAGE-MAKER-384\u002FFEATURED-IMAGE-MAKER-384","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_360,c_scale\u002Ff_webp,q_auto\u002Fv1772526574\u002Fimages\u002FFEATURED-IMAGE-MAKER-384\u002FFEATURED-IMAGE-MAKER-384.png?_i=AA",{"altText":259},{"name":205,"slug":206,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":269},[],[271],{"name":180,"slug":181,"uri":182,"description":171,"postsCount":183},[],[274,294,309,324,341,356,374,388,403,417],{"id":183,"title":275,"date":276,"excerpt":277,"wordCount":278,"uri":279,"slug":280,"cloudinaryAssetId":281,"featuredImageOriginalUrl":282,"featuredImageMetadata":283,"author":284,"categories":288,"relatedPosts":293},"Barclays ramène la note de l'action Blue Owl à \"Equal Weight\" alors que la chute du cours de l'action se poursuit","2026-03-03 11:59:00","Barclays abaisse la note de Blue Owl Capital en raison d'un fort ralentissement des entrées de capitaux dans les BDC non cotées et d'une forte augmentation des rachats. L'action a baissé de 50 % au cours de l'année écoulée en raison des craintes liées au crédit.",775,"\u002Fblog\u002Fbarclays-cuts-blue-owl-nyse-owl-stock-rating-equal-weight-price-plunge","barclays-cuts-blue-owl-nyse-owl-stock-rating-equal-weight-price-plunge","images\u002FOWL-stock-1\u002FOWL-stock-1","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772533744\u002Fimages\u002FOWL-stock-1\u002FOWL-stock-1.png?_i=AA",{"altText":275},{"name":285,"slug":286,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":287},"Aditya Raghunath","adityatikr",[],[289],{"name":290,"slug":291,"uri":292,"description":171,"postsCount":183},"Investissement Général","general-investing","\u002Fblog\u002Fcategory\u002Fgeneral-investing",[],{"id":183,"title":295,"date":296,"excerpt":297,"wordCount":298,"uri":299,"slug":300,"cloudinaryAssetId":301,"featuredImageOriginalUrl":302,"featuredImageMetadata":303,"author":304,"categories":306,"relatedPosts":308},"L'action Novo Nordisk atteint son plus bas niveau en 52 semaines, Goldman Sachs la rétrograde à \"neutre\".","2026-03-03 10:55:00","L'action Block a augmenté de plus de 20 % après que la société fintech a annoncé qu'elle allait licencier plus de 4 000 employés, soit environ la moitié de ses effectifs.",655,"\u002Fblog\u002Fnovo-nordisk-nyse-nvo-stock-hits-52-week-low-as-goldman-sachs-downgrades-it-to-neutral","novo-nordisk-nyse-nvo-stock-hits-52-week-low-as-goldman-sachs-downgrades-it-to-neutral","images\u002FNVO-stock_954941bea1\u002FNVO-stock_954941bea1","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772532602\u002Fimages\u002FNVO-stock_954941bea1\u002FNVO-stock_954941bea1.png?_i=AA",{"altText":295},{"name":285,"slug":286,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":305},[],[307],{"name":290,"slug":291,"uri":292,"description":171,"postsCount":183},[],{"id":183,"title":310,"date":311,"excerpt":312,"wordCount":313,"uri":314,"slug":315,"cloudinaryAssetId":316,"featuredImageOriginalUrl":317,"featuredImageMetadata":318,"author":319,"categories":321,"relatedPosts":323},"Le financement massif d'OpenAI déclenche la chute des actions d'Amazon","2026-03-02 10:30:00","L'action d'Amazon a chuté après la levée de fonds de 110 milliards de dollars d'OpenAI, malgré l'engagement d'Amazon à hauteur de 50 milliards de dollars et la conclusion d'un accord de partenariat majeur avec AWS.",831,"\u002Fblog\u002Fopenai-massive-funding-round-triggers-selloff-in-amazon-nasdaq-amzn-stock","openai-massive-funding-round-triggers-selloff-in-amazon-nasdaq-amzn-stock","images\u002FAMZN-stock-1\u002FAMZN-stock-1","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772278707\u002Fimages\u002FAMZN-stock-1\u002FAMZN-stock-1.png?_i=AA",{"altText":310},{"name":285,"slug":286,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":320},[],[322],{"name":290,"slug":291,"uri":292,"description":171,"postsCount":183},[],{"id":183,"title":325,"date":326,"excerpt":327,"wordCount":328,"uri":329,"slug":330,"cloudinaryAssetId":331,"featuredImageOriginalUrl":332,"featuredImageMetadata":333,"author":334,"categories":338,"relatedPosts":340},"L'action Chime bondit de 14 % sur la voie de la rentabilité selon les GAAP : voici où l'action pourrait se diriger en 2026","2026-03-01 15:00:00","Les actions de Chime Financial (CHYM) sont en train d'enregistrer une forte hausse après la publication de leurs résultats, suite à la publication d'un rapport sur le quatrième trimestre qui a fait date.",743,"\u002Fblog\u002Fchime-stock-surges-14-on-path-to-gaap-profitability-heres-where-the-stock-could-be-headed-in-2026","chime-stock-surges-14-on-path-to-gaap-profitability-heres-where-the-stock-could-be-headed-in-2026","images\u002F21-2\u002F21-2","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772322176\u002Fimages\u002F21-2\u002F21-2.png?_i=AA",{"altText":325},{"name":335,"slug":336,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":337},"Wiltone Asuncion","wiltonetikr",[],[339],{"name":290,"slug":291,"uri":292,"description":171,"postsCount":183},[],{"id":183,"title":342,"date":343,"excerpt":344,"wordCount":345,"uri":346,"slug":347,"cloudinaryAssetId":348,"featuredImageOriginalUrl":349,"featuredImageMetadata":350,"author":351,"categories":353,"relatedPosts":355},"L'action de Crescent Energy bondit de 7 % grâce à des synergies doublées dans le Permien : Voici où l'action pourrait aller en 2026","2026-03-01 14:50:00","Crescent Energy Company (CRGY) aborde l'année 2026 en tant qu'opérateur multi-bassins à grande échelle, après avoir réalisé des transactions d'une valeur de près de 5 milliards de dollars. ",816,"\u002Fblog\u002Fcrescent-energy-stock-surges-7-on-doubled-permian-synergies-heres-where-the-stock-could-go-in-2026","crescent-energy-stock-surges-7-on-doubled-permian-synergies-heres-where-the-stock-could-go-in-2026","images\u002F20-2\u002F20-2","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772322164\u002Fimages\u002F20-2\u002F20-2.png?_i=AA",{"altText":342},{"name":335,"slug":336,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":352},[],[354],{"name":290,"slug":291,"uri":292,"description":171,"postsCount":183},[],{"id":183,"title":357,"date":358,"excerpt":359,"wordCount":360,"uri":361,"slug":362,"cloudinaryAssetId":363,"featuredImageOriginalUrl":364,"featuredImageMetadata":365,"author":366,"categories":368,"relatedPosts":373},"En baisse de 25 % par rapport à son plus haut niveau historique, l'action Capital One peut-elle offrir de meilleurs rendements en 2026 ?","2026-03-03 11:25:00","L'action Capital One pourrait générer des rendements de 30 % d'ici 2028, l'intégration de Discover et l'acquisition de Brex débloquant la croissance du réseau de paiements et l'expansion des services bancaires aux entreprises.",1309,"\u002Fblog\u002Fdown-25-from-all-time-high-can-capital-one-nyse-stock-deliver-better-returns-in-2026","down-25-from-all-time-high-can-capital-one-nyse-stock-deliver-better-returns-in-2026","images\u002FCOF-stock\u002FCOF-stock","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772516734\u002Fimages\u002FCOF-stock\u002FCOF-stock.png?_i=AA",{"altText":357},{"name":285,"slug":286,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":367},[],[369],{"name":370,"slug":371,"uri":372,"description":171,"postsCount":183},"Évaluation","valuation","\u002Fblog\u002Fcategory\u002Fvaluation",[],{"id":183,"title":375,"date":296,"excerpt":376,"wordCount":377,"uri":378,"slug":379,"cloudinaryAssetId":380,"featuredImageOriginalUrl":381,"featuredImageMetadata":382,"author":383,"categories":385,"relatedPosts":387},"En hausse de 20 % au cours des 12 derniers mois, l'action Synchrony Financial peut-elle évoluer à la hausse en 2026 ?","En hausse de 20% sur 12 mois, Synchrony Financial est prometteur avec la croissance du partenariat avec Walmart. Notre modèle prévoit une hausse de 27% à 87 $ d'ici décembre 2028. Analyse à l'intérieur.",1261,"\u002Fblog\u002Fup-20-in-last-12-months-can-synchrony-financial-syf-stock-deliver-further-in-2026","up-20-in-last-12-months-can-synchrony-financial-syf-stock-deliver-further-in-2026","images\u002FSYF-stock\u002FSYF-stock","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772512295\u002Fimages\u002FSYF-stock\u002FSYF-stock.png?_i=AA",{"altText":375},{"name":285,"slug":286,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":384},[],[386],{"name":370,"slug":371,"uri":372,"description":171,"postsCount":183},[],{"id":183,"title":389,"date":390,"excerpt":391,"wordCount":392,"uri":393,"slug":394,"cloudinaryAssetId":395,"featuredImageOriginalUrl":396,"featuredImageMetadata":397,"author":398,"categories":400,"relatedPosts":402},"En hausse de 42 % en 3 ans, l'action de Raymond James Financial peut-elle continuer à progresser ?","2026-03-03 09:55:00","L'action Raymond James a baissé de 10 % en 12 mois. Un fort recrutement, 31 milliards de dollars de nouveaux actifs nets signalent une reprise. Notre modèle prévoit une hausse de 21 % pour atteindre 185 $ d'ici septembre 2028.",1234,"\u002Fblog\u002Fup-42-in-3-years-can-raymond-james-financial-nyse-rjf-stock-deliver-further","up-42-in-3-years-can-raymond-james-financial-nyse-rjf-stock-deliver-further","images\u002FRJF-stock_9542509878\u002FRJF-stock_9542509878","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772467602\u002Fimages\u002FRJF-stock_9542509878\u002FRJF-stock_9542509878.png?_i=AA",{"altText":389},{"name":285,"slug":286,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":399},[],[401],{"name":370,"slug":371,"uri":372,"description":171,"postsCount":183},[],{"id":183,"title":404,"date":390,"excerpt":405,"wordCount":406,"uri":407,"slug":408,"cloudinaryAssetId":409,"featuredImageOriginalUrl":410,"featuredImageMetadata":411,"author":412,"categories":414,"relatedPosts":416},"En hausse de 19 % au cours des 12 derniers mois, les valeurs financières régionales peuvent-elles encore progresser en 2026 ?","Des bénéfices solides au quatrième trimestre et un taux de rendement des capitaux propres de 18 % placent Regions Financial en position de croissance. Notre modèle prévoit une hausse de 26 % pour atteindre 35 $ d'ici 2028. L'action RF peut-elle tenir ses promesses en 2026 ?",1264,"\u002Fblog\u002Fup-19-in-last-12-months-can-regional-financial-nyse-stock-deliver-better-returns-in-2026","up-19-in-last-12-months-can-regional-financial-nyse-stock-deliver-better-returns-in-2026","images\u002FRF-stock_953648bd63\u002FRF-stock_953648bd63","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772446487\u002Fimages\u002FRF-stock_953648bd63\u002FRF-stock_953648bd63.png?_i=AA",{"altText":404},{"name":285,"slug":286,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":413},[],[415],{"name":370,"slug":371,"uri":372,"description":171,"postsCount":183},[],{"id":183,"title":418,"date":419,"excerpt":420,"wordCount":421,"uri":422,"slug":423,"cloudinaryAssetId":424,"featuredImageOriginalUrl":425,"featuredImageMetadata":426,"author":427,"categories":429,"relatedPosts":431},"En baisse de 65 % par rapport à son plus haut niveau historique, l'action Brown-Forman peut-elle offrir de meilleurs résultats en 2026 ?","2026-03-03 09:45:00","L'action Brown-Forman pourrait atteindre 36 dollars d'ici 2028 grâce au succès du Blackberry de Jack Daniel et à la croissance des marchés émergents, malgré des vents contraires à court terme dans le secteur de la consommation.",1334,"\u002Fblog\u002Fdown-65-from-all-time-high-can-brown-forman-nyse-stock-deliver-better-results-in-2026","down-65-from-all-time-high-can-brown-forman-nyse-stock-deliver-better-results-in-2026","images\u002FBFB-stock\u002FBFB-stock","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772433508\u002Fimages\u002FBFB-stock\u002FBFB-stock.png?_i=AA",{"altText":418},{"name":285,"slug":286,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":428},[],[430],{"name":370,"slug":371,"uri":372,"description":171,"postsCount":183},[]]